



Date: 02/11/2023

To,

National Stock Exchange of India Ltd.

Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai- 400 051

Symbol: MOREPENLAB

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400 001

Scrip Code: 500288

Subject: Outcome of the meeting of the Board of Directors of the company

Dear Sir/Madam,

This is to inform you that the Board of Directors of the company, in their meeting held on Thursday, 2nd November 2023 (*commenced at 11:30 A.M. and concluded at 1:55 P.M.*), have, *inter-alia*, considered and approved the unaudited standalone and consolidated financial results of the company for the quarter and half year ended 30th September 2023 ('Results'), pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The 'Results' along-with 'Limited Review Reports' issued by the Statutory Auditors of the company, are enclosed herewith.

Kindly take aforesaid on record.

Thanking you,

Yours faithfully,

For Morepen Laboratories Limited

Vipul Kumar Srivastava
Company Secretary
Membership no. F-12148

Encl.: a/a.

Morepen Laboratories Limited

CIN No: L24231 HP1984PLC006028

Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector 20, Gurugram, Haryana-122016, INDIA
Tel.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com

Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA
Tel.: +91-1795-266401-03, 244590, Fax: +91-1795-244591, E-mail: plants@morepen.com

S.P. Babuta and Associates

Chartered Accountants

#240, Sector 21-A, Chandigarh-160022, Tel: 91 172 2704943, 2713814, Email ID : sphabuta@hotmail.com, Website : www.babuta.com

Limited Review Report – Consolidated Financial Results

Review Report to

The Board of Directors

Morepen Laboratories Limited

1. We have reviewed the accompanying statement of consolidated financial results of Morepen Laboratories Limited (the “Parent”) and its subsidiaries (the Parent and its subsidiaries together referred to as the “Group”) for the quarter ended Sep 30, 2023 (the “Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “Listing Regulations”).
2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) “Interim Financial Reporting” prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. This Statement includes the results of the following Group entities:

- Morepen Laboratories Limited (the “Parent”)
- Dr. Morepen Limited (Indian Subsidiary)
- Total Care Limited (Indian Subsidiary)
- Morepen Devices Limited (Indian Subsidiary)
- Morepen Rx Ltd. (Indian Subsidiary)
- Morepen Bio Inc. (Foreign Subsidiary)



5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of four subsidiaries i.e. Total Care Limited, Morepen Devices Limited, Morepen Rx Ltd. and Morepen Bio Inc., included in the statement, whose interim financial results reflect total assets (before consolidation adjustments) of Rs. 6177.81 lakhs as at September 30, 2023 and total revenues (before consolidation adjustments) of Rs. 4449.07 lakhs and Rs.9139.49 lakhs, total profit/(loss) after tax (before consolidation adjustments) of Rs.(34.19) lakhs and Rs.16.35 lakhs and total comprehensive income (before consolidation adjustments) of Rs. (28.51) lakhs and Rs.22.03 lakhs for the quarter ended September 30, 2023 and for the period April 01, 2023 to September 30, 2023 respectively. The interim financial results of these four subsidiaries have been reviewed by their auditors whose report has been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above.

We have also not reviewed the financial results of above mentioned four subsidiaries and their financial results are based on management certified financial information.

Our conclusion on the Statement is not modified in respect of the above matter.

For S.P.Babuta & Associates
Chartered Accountants
F. No: 007657N



[Signature]
CA S. P. Babuta
Managing Partner

FCA, AITIA, IP, DISA, CCA
GST Cert, Forensic Auditor
Membership No.: 086348

Dated: 02/11/2023
Place: Gurugram, Haryana

UDIN No.: 23086348 BGYBHJ 5506

Morepen Laboratories Limited
CIN- L24231HP1984PLC006028
Statement of Unaudited Financial Results - Consolidated
For the Quarter & Half Year Ended 30th September, 2023

(Rs.in Lakhs, except per share data)						
Particulars	Quarter Ended			Half Year Ended		Year Ended
	30.09.2023	30.06.2023	30.09.2022	30.09.2023	30.09.2022	31.03.2023
	(Unaudited)					(Audited)
1. Income						
Income from operations (Net)	42176.87	40103.62	40297.80	82280.49	70537.97	141753.00
Other Income	323.71	241.99	87.44	565.70	178.76	613.34
Total Income	42500.58	40345.61	40385.24	82846.19	70716.73	142366.34
2. Expenditure						
a) Cost of Material Consumed	22736.37	20008.38	20075.42	42744.75	39838.86	78140.92
b) Purchase of stock - in - trade	4360.70	5771.18	4142.39	10131.88	7320.05	15785.21
c) Changes in inventories of Finished goods, Work -in-progress and Stock-in-trade	180.22	329.15	3313.59	509.37	1303.00	1648.31
d) Employee Benefits Expenses	4331.70	4340.86	3907.97	8672.56	7464.57	15468.05
e) Finance Cost	45.79	28.27	47.41	74.06	86.87	198.08
f) Depreciation and Amortization	768.67	771.42	700.27	1540.09	1375.94	2793.04
g) Power and Fuel	788.44	692.33	557.96	1480.77	1100.16	2377.71
h) Travelling Expenses	565.94	459.49	418.02	1025.43	872.20	1683.12
i) Selling and Distribution Expenses	3091.80	2867.65	3018.30	5959.45	4284.45	9301.36
j) Other Expenses	2762.78	3025.70	1973.21	5788.48	4009.21	9395.01
Total Expenditure	39632.41	38294.43	38154.54	77926.84	67655.31	136790.81
3. Profit before Tax (1-2)	2868.17	2051.18	2230.70	4919.35	3061.42	5575.53
4. Tax Expense						
Current Tax	742.59	587.89	649.61	1330.48	917.34	1681.78
Earlier Periods Tax	-	-	-	-	-	5.86
Deferred Tax	-	-	-	-	-	20.34
Total Tax	742.59	587.89	649.61	1330.48	917.34	1707.98
5. Net Profit for the period (3-4)	2125.58	1463.29	1581.09	3588.87	2144.08	3867.55
6. Share of Minority Interest in (Profit)/ Loss	(0.03)	(0.03)	(0.03)	(0.06)	(0.05)	0.03
7. Net Profit after Minority Interest (5-6)	2125.61	1463.32	1581.12	3588.93	2144.13	3867.52
8. Other Comprehensive Income/ (Loss) (OCI)						
Items that will not be reclassified to Profit & Loss	(114.03)	141.73	(142.37)	27.70	(45.90)	(200.62)
Income Tax	(32.51)	40.47	(39.25)	7.96	(13.27)	(52.59)
Other Comprehensive Income/ (Loss) (Net of Tax)	(81.52)	101.26	(103.12)	19.74	(32.63)	(148.03)
9. Total Comprehensive Income (7+8)	2044.09	1564.58	1478.00	3608.67	2111.50	3719.49
10. Paid-up Equity Share Capital of Face Value of Rs.2/- each	10222.71	10222.71	10222.71	10222.71	10222.71	10222.71
11. Other Equity						65068.10
12. Earning Per Share (in Rs.)						
- Basic	0.42	0.29	0.33	0.71	0.45	0.77
- Diluted	0.42	0.29	0.33	0.71	0.43	0.77

Notes :

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 02, 2023. A Limited review of the same has been carried out by the Statutory Auditors.
- During the quarter under review, formulation distribution business was transferred to the wholly owned subsidiary of the company i.e. Morepen Rx Limited. The current quarter and period to date financial results and related information includes that of, Morepen Rx Limited.
- The Company is engaged in the Pharmaceutical Business Segment.



4. Statement of Assets and Liabilities -		(Rs. in Lakhs)	
Particulars		(Unaudited)	(Audited)
		As at	
		30.09.2023	31.03.2023
A ASSETS			
I. Non Current Assets			
(a) Property, Plant and Equipment		19321.09	16699.90
(b) Capital Work in Progress		1999.86	1701.37
(c) Goodwill		7447.42	7447.42
(d) Other Intangible Assets		1973.98	2549.86
(d) Financial Assets :			
(i) Investment		-	-
(ii) Loans		4.95	4.95
(iii) Other Financial Assets		637.77	637.77
(iv) Other Non-Current Assets		6440.47	6391.77
	Non- Current Assets	37825.54	35433.04
II. Current Assets			
(a) Inventories		23082.61	22888.63
(b) Financial Assets :			
(i) Investments		25.00	-
(ii) Trade receivables		28447.37	26324.70
(iii) Cash and cash equivalents		2328.63	2166.58
(iv) Bank Balance other than Cash and Cash Equivalents		3430.73	3463.97
(v) Loans		25.44	27.37
(vi) Others Financial Assets		652.82	551.27
(c) Other Current Assets		23560.03	20193.95
	Current Assets	81552.63	75616.47
Total		119378.17	111049.51
B EQUITY AND LIABILITIES			
I. EQUITY			
(a) Equity Share Capital		10222.71	10222.71
(b) Other Equity		68676.77	65068.10
	Equity	78899.48	75290.81
II. Minority Interest		(46.10)	(46.04)
III. Non - Current Liabilities			
(a) Financial Liabilities :			
(i) Borrowings		126.75	93.35
(ii) Other Financial Liabilities		418.76	352.02
(b) Deferred Tax Liabilities (Net)		268.60	268.60
(c) Provisions		3090.09	2974.46
	Non- Current Liabilities	3904.20	3688.43
IV. Current Liabilities			
(a) Financial Liabilities :			
(i) Borrowings		2648.79	2423.06
(ii) Trade Payables			
- Total outstanding dues of MSME		128.28	225.12
- Total outstanding dues of creditors other than MSME		24258.34	22462.81
(iii) Other Financial Liabilities		4480.62	5012.64
(iv) Other Current liabilities		1694.43	368.57
(b) Provisions		3410.13	1624.11
	Current Liabilities	36620.59	32116.31
Total		119378.17	111049.51



5. Statement of Cash Flows for the Period Ended 30th September, 2023		(Rs. in Lakhs)	
Particulars		Unaudited	
		Half Year Ended	
		30.09.2023	30.09.2022
A. CASH FLOWS FROM OPERATING ACTIVITIES :			
Profit before Tax		4919.35	3061.42
Adjustments for :			
Depreciation & Amortisation		1540.09	1375.94
Provision for Employee benefit		27.70	(45.90)
Finance Cost		74.06	86.87
Minority Interest		(0.06)	(0.05)
Operating Profit before changes in Current Assets and Liabilities		6561.14	4478.28
Changes in Current Assets and Liabilities -			
Trade Receivables		(2122.67)	(412.67)
Loans, Bank balance other than cash & Cash equivalent and other Current Assets		(3434.39)	(190.55)
Inventories		(193.98)	3454.78
Current Liabilities		4278.55	(18039.79)
Cash generated from Operations		5088.65	(10709.95)
Tax Expense (Net)		(1338.44)	(904.07)
NET CASH FLOWS FROM OPERATING ACTIVITIES		3750.21	(11614.02)
B. CASH FLOWS FROM INVESTING ACTIVITIES:			
Purchase of Property, Plant & Equipments		(3615.24)	(1444.31)
Purchase/Addition of Intangibles (Net)		(268.65)	(605.20)
Sales/(Purchase) of Investments (Net)		(25.00)	-
Loans		1.93	-
Investment in Other Non-Current Assets		(48.70)	(863.13)
NET CASH FLOWS FROM INVESTING ACTIVITIES		(3955.66)	(2912.64)
C. CASH FLOWS FROM FINANCING ACTIVITIES:			
Finance Cost		(74.06)	(86.87)
Proceeds (Repayments) of Borrowings (Net)		259.13	424.24
Issuance of Equity		-	13715.21
Change in Other Financial Liabilities & Provisions (Non-Current)		182.43	2.18
NET CASH FLOWS FROM FINANCING ACTIVITIES		367.50	14054.76
Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)		162.05	(471.90)
Cash and Cash Equivalents as at Beginning of the period		2166.58	1580.26
Cash and Cash Equivalents as at End of the period		2328.63	1108.36
Bank Balances other than Cash and Cash Equivalents		3430.73	2956.53
		For and on behalf of the Board of Directors	
Place : Gurugram, Haryana Date : November 02, 2023   (Sushil Suri) Chairman & Managing Director			

S.P. Babuta and Associates

Chartered Accountants

#240, Sector 21-A, Chandigarh-160022, Tel: 91 172 2704943, 2713814, Email ID : spbabuta@hotmail.com, Website : www.babuta.com

Limited Review Report – Standalone Financial Results

**Review Report to
The Board of Directors
Morepen Laboratories Limited**

1. We have reviewed the accompanying statement of standalone financial results of Morepen Laboratories Limited (the "Company") for the quarter ended Sep 30, 2023 (the "Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.P.Babuta & Associates
Chartered Accountants
F. No: 007657N




CA S. P. Babuta
Managing Partner
FCA, AIIA, IP, DISA, CCA
GST Cert, Forensic Auditor
Membership No.: 086348

Dated: 02/11/2023
Place: Gurugram, Haryana

UDIN No.: 23086348BGYBHJ2992

Morepen Laboratories Limited CIN- L24231HP1984PLC006028 Statement of Unaudited Financial Results - Standalone For the Quarter & Half Year Ended 30th September, 2023						
(Rs.in Lakhs, except per share data)						
	Particulars	Quarter Ended			Half Year Ended	
		30.09.2023	30.06.2023	30.09.2022	30.09.2023	31.03.2023
		(Unaudited)			(Audited)	
1.	Income					
	Income from operations (Net)	38125.76	36910.29	38334.23	75036.05	133888.33
	Other Income	283.75	208.39	87.44	492.14	575.88
	Total Income	38409.51	37118.68	38421.67	75528.19	134464.21
2.	Expenditure					
	a) Cost of Material Consumed	22736.37	20008.38	20075.42	42744.75	78140.92
	b) Purchase of stock - in - trade	1789.39	3262.26	3209.96	5051.65	10506.93
	c) Changes in inventories of Finished goods, Work -in-progress and Stock-in-trade	45.10	262.10	3059.16	307.20	1653.86
	d) Employee Benefits Expenses	3872.63	4107.08	3705.30	7979.71	14619.30
	e) Finance Cost	45.49	28.27	47.41	73.76	198.08
	f) Depreciation and Amortization	481.05	489.27	446.36	970.32	1800.57
	g) Power and Fuel	788.44	692.33	557.96	1480.77	2377.71
	h) Travelling Expenses	448.70	400.88	324.84	849.58	1429.51
	i) Selling and Distribution Expenses	2812.25	2767.60	2674.76	5579.85	8490.82
	j) Other Expenses	2656.68	2929.28	2018.47	5585.96	8942.3
	Total Expenditure	35676.1	34947.45	36119.64	70623.55	128160
	Profit before extraordinary items & tax	2733.41	2171.23	2302.03	4904.64	6304.21
3.	Profit before Tax (1-2)	2733.41	2171.23	2302.03	4904.64	6304.21
4.	Tax Expense					
	Current Tax	741.02	586.23	649.61	1,327.25	1,659.99
	Earlier Periods Tax	-	-	-	-	(0.41)
	Deferred Tax	-	-	-	-	20.34
	Total Tax	741.02	586.23	649.61	1,327.25	1,679.92
5.	Net Profit for the period (3-4)	1992.39	1585.00	1652.42	3577.39	4624.29
	Other Comprehensive Income (OCI)					
	Items that will not be reclassified to Profit & Loss	(120.43)	149.90	(139.12)	29.47	(197.37)
	Income Tax	(32.51)	40.47	(39.25)	7.96	(52.59)
6.	Other Comprehensive Income (Net of Tax)	(87.92)	109.43	(99.87)	21.51	(144.78)
	Total Comprehensive Income (5+6)	1904.47	1694.43	1552.55	3598.90	4479.51
7.	Paid-up Equity Share Capital of Face Value of Rs.2/- each	10222.71	10222.71	10222.71	10222.71	10222.71
8.	Other Equity					67788.71
9.	Earning Per Share (in Rs.)					
	- Basic	0.39	0.31	0.35	0.70	0.92
	- Diluted	0.39	0.31	0.35	0.70	0.92
Notes :						
1.	The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 02, 2023. A Limited review of the same has been carried out by the Statutory Auditors.					
2.	During the quarter under review, formulation distribution business was transferred to the wholly owned subsidiary of the company i.e. Morepen Rx Limited and its revenue ceases to be a part of standalone financial results from date of business transfer.					
3.	The Company is engaged in the Pharmaceutical Business Segment.					



4. Statement of Assets and Liabilities -		(Rs. in Lakhs)	
Particulars		(Unaudited)	(Audited)
		As at	
		30.09.2023	31.03.2023
A ASSETS			
I. Non Current Assets			
(a) Property, Plant and Equipment		19239.33	16608.55
(b) Capital Work in Progress		1999.86	1701.37
(c) Other Intangible Assets		197.73	473.54
(d) Financial Assets :			
(i) Investment		12487.72	11784.48
(ii) Loans		4.95	4.95
(iii) Other Financial Assets		481.86	506.29
(iv) Other Non-Current Assets		6438.97	6390.27
	Non- Current Assets	40850.42	37469.45
II. Current Assets			
(a) Inventories		21809.07	21134.90
(b) Financial Assets :			
(i) Investments		25.00	-
(ii) Trade receivables		24515.32	25547.12
(iii) Cash and cash equivalents		2175.31	2126.36
(iv) Bank Balance other than Cash and Cash Equivalents		3414.05	3463.97
(v) Loans		25.44	27.37
(vi) Others		639.84	550.69
(c) Other Current Assets		22978.12	20234.39
	Current Assets	75582.15	73084.80
Total		116432.57	110554.25
B EQUITY AND LIABILITIES			
I. EQUITY			
(a) Equity Share Capital		10222.71	10222.71
(b) Other Equity		71387.61	67788.71
	Equity	81610.32	78011.42
II. Non - Current Liabilities			
(a) Financial Liabilities :			
(i) Borrowings		126.75	93.35
(ii) Other Financial Liabilities		42.75	196.50
(b) Deferred Tax Liabilities (Net)		268.60	268.60
(c) Provisions		2834.19	2886.79
	Non- Current Liabilities	3272.29	3445.24
III. Current Liabilities			
(a) Financial Liabilities :			
(i) Borrowings		2565.99	2423.06
(ii) Trade Payables			
- Total outstanding dues of MSME		121.04	234.36
- Total outstanding dues of creditors other than MSME		21381.15	21075.32
(iii) Other Financial Liabilities		3954.50	3741.21
(iv) Other Current liabilities		314.19	132.24
(b) Provisions		3213.09	1491.40
	Current Liabilities	31549.96	29097.59
Total		116432.57	110554.25



5. Statement of Cash Flows for the Period Ended 30th September, 2023		(Rs. in Lakhs)	
Particulars	Unaudited		
	Half Year Ended		
	30.09.2023	30.09.2022	
A. CASH FLOWS FROM OPERATING ACTIVITIES :			
Profit before Tax	4904.64	3257.38	
Adjustments for :			
Depreciation & Amortisation	970.32	883.42	
Provision for Employee benefit	29.47	(46.40)	
Finance Cost	73.76	86.87	
Operating Profit before changes in Current Assets and Liabilities	5978.19	4181.27	
Changes in Current Assets and Liabilities -			
Trade Receivables	1031.80	(1862.61)	
Loans, Bank balance other than cash & Cash equivalent and other Current Assets	(2782.96)	(1723.00)	
Inventories	(674.17)	2606.50	
Current Liabilities	2309.44	(15483.99)	
Cash generated from Operations	5862.30	(12281.83)	
Tax Expense (Net)	(1335.21)	(904.07)	
NET CASH FLOWS FROM OPERATING ACTIVITIES	4527.09	(13185.90)	
B. CASH FLOWS FROM INVESTING ACTIVITIES:			
Purchase of Property, Plant & Equipments	(3614.80)	(1437.83)	
Purchase/Addition of Intangibles (Net)	(8.98)	(2.03)	
Sales/(Purchase) of Investments (Net)	(728.24)	-	
Loans	1.93	-	
Investment in Other Non-Current Assets	(24.27)	2.16	
NET CASH FLOWS FROM INVESTING ACTIVITIES	(4374.36)	(1437.70)	
C. CASH FLOWS FROM FINANCING ACTIVITIES:			
Finance Cost	(73.76)	(86.87)	
Proceeds (Repayments) of Borrowings (Net)	176.33	424.24	
Issuance of Equity	-	13715.21	
Change in Other Financial Liabilities & Provisions (Non-Current)	(206.35)	75.78	
NET CASH FLOWS FROM FINANCING ACTIVITIES	(103.78)	14128.36	
Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	48.95	(495.24)	
Cash and Cash Equivalents as at Beginning of the period	2126.36	1538.03	
Cash and Cash Equivalents as at End of the period	2175.31	1042.79	
Bank Balances other than Cash and Cash Equivalents	3414.05	2956.43	
For and on behalf of the Board of Directors			
			
Place : Gurugram, Haryana Date : November 02, 2023		(Sushil Suri) Chairman & Managing Director	